Streetbeat News

CING

Cingulate Inc.

https://www.cingulate.com

Industry

Biotechnology

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Open

4.19

Mkt cap

13M

Volume

25K

High

4.19

P/E Ratio

-0.09

52-wk high

152.40

Low

4.01

Div yield

N/A

52-wk low

1.80

HC Wainwright & Co. analyst Raghuram Selvaraju maintains a Buy rating on Cingulate (NASDAQ:CING) but lowers the price target from $5.5 to $3.5.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 10:27 am

Insiders at four penny stocks, SpringBig Holdings (OTC:SBIG), Ocean Power Technologies (NYSE:OPTT), Cingulate Inc. (NASDAQ:CING), and Vivani Medical (NASDAQ:VANI), have recently made notable purchases. This could indicate their confidence in the companies' prospects despite recent downbeat quarterly results and wider losses.

Portfolio Pulse from Lisa Levin

September 19, 2023 | 12:49 pm

Several stocks experienced significant pre-market trading movements. Acelyrin, Inc. (SLRN) shares fell 58.5% due to a failed primary endpoint. Sight Sciences, Inc. (SGHT) shares fell 29.3% after issuing below-estimate Q3 revenue guidance and cutting FY23 revenue guidance. Versus Systems Inc. (VS), CXApp Inc. (CXAI), Eightco Holdings Inc. (OCTO), Cingulate Inc. (CING), Solowin Holdings (SWIN), DatChat, Inc. (DATS), Canopy Growth Corporation (CGC), and Oracle Corporation (ORCL) also saw pre-market trading declines.

Portfolio Pulse from Lisa Levin

September 12, 2023 | 12:00 pm

Cingulate Inc (NASDAQ: CING) has priced its $4-million public offering at around 58 cents per share, which includes 6.93 million shares and Series A and Series B warrants. The company also announced full results from the Phase 3 adult efficacy and safety study of its lead candidate, CTx-1301 (dexmethylphenidate), for ADHD. The data did not achieve statistical significance on the primary efficacy endpoint but showed a trend toward significance in improving PERMP scores. Cingulate shares were down 5.14% at 55 cents midday Monday.

Portfolio Pulse from Vandana Singh

September 11, 2023 | 5:17 pm

Cingulate Therapeutics has priced its offering of 6,925,208 shares at $0.5776 per share.

Portfolio Pulse from Bill Haddad

September 11, 2023 | 1:23 pm

Shares of Tenon Medical, Inc. (TNON), Axcella Health Inc. (AXLA), Courtside Group, Inc. (PODC), Impel Pharmaceuticals Inc. (IMPL), MIRA Pharmaceuticals, Inc. (MIRA), Nuwellis, Inc. (NUWE), Hitek Global Inc. (HKIT), WANG & LEE GROUP, Inc. (WLGS), AEye, Inc. (LIDR), and Magenta Therapeutics, Inc. (MGTA) are trading lower in pre-market. The drop in TNON's shares is due to a proposed public offering of common stock.

Portfolio Pulse from Lisa Levin

September 11, 2023 | 12:10 pm

Cingulate Inc. (NASDAQ:CING) announced full results from the Phase 3 adult efficacy and safety study of its lead candidate, CTx-1301 (dexmethylphenidate), for the treatment of ADHD. The study did not achieve statistical significance on the primary efficacy endpoint but demonstrated a trend toward significance in improving PERMP scores with CTx-1301 compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 10:01 am

During Friday's after-market session, several health care stocks experienced significant movement. Cingulate (CING), Clene (CLNN), Elutia (ELUT), Etao International Co (ETAO), Atossa Therapeutics (ATOS), and Renalytix (RNLX) saw their stocks rise, with Cingulate leading the gainers with a 19.4% increase. On the other hand, Tenon Medical (TNON), Axcella Health (AXLA), Alzamend Neuro (ALZN), NRX Pharmaceuticals (NRXP), Trevena (TRVN), and Inspire Veterinary (IVP) saw their stocks fall, with Tenon Medical leading the losers with a 30.3% decrease.

Portfolio Pulse from Benzinga Insights

September 08, 2023 | 9:31 pm

Cingulate Therapeutics has announced the presentation of full trial results from its Phase 3 adult efficacy and safety trial of CTx-1301 for ADHD at Psych Congress 2023.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2023 | 12:13 pm

Several healthcare stocks experienced significant movement in Thursday's after-market session. TRACON Pharma, Alpha Tau Medical, Avalo Therapeutics, Neoleukin Therapeutics, GRI Bio, and Assure Hldgs saw increases, while Athersys, Incannex Healthcare, Bone Biologics, Renovaro Biosciences, Cingulate, and VolitionRX experienced decreases. Q2 earnings reports were recently released for several of these companies.

Portfolio Pulse from Benzinga Insights

August 17, 2023 | 9:32 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.